Skip to main content

Table 5 Burden of Pseudomonas aeruginosa pneumonia stratified for multidrug-resistance

From: Measuring the in-hospital costs of Pseudomonas aeruginosa pneumonia: methodology and results from a German teaching hospital

 

Hospital-acquired cases (HAP)

Community-acquired cases (CAP) where the infection was not the main diagnosis

Community-acquired cases (CAP) where the infection was the main diagnosis

Non-MDR-HAP (N = 126)

MDR-HAP (N = 15)

Non-MDR-CAP (N = 48)

MDR-CAP (N = 15)

Non-MDR- CAP (N = 27)

MDR –CAP (N = 5)

Additional costs (in €)

19,448.3***

12,875.3

4051.7***

27,251.06***

6121.2***

12,981.7

[12,472.7, 26,423.9]

[− 3890.0, 29,640.6]

[1971.6, 6131.7]

[7732.4, 46,769.6]

[2657.6, 9584.8]

[−25,078.8, 51,042.2]

Additional reimbursement (in €)

17,729.8***

4728.6

2647.5***

18,070.3***

5077.4***

7676.6

[9943.0, 25,516.7]

[− 7346.2, 16,803.5]

[1196.5, 4098.6]

[12,582.8, 23,557.7]

[1979.8, 8175.0]

[−30,929.8, 46,283.1]

Additional length of stay (in days)

9.524***

6.693**

5.102***

15.483***

9***

25

[6.494, 12.554]

[1.532, 11.854]

[2.498, 7.705]

[10.490, 20.477]

[5.302, 12.697]

[−10.087, 60.087]

N

555

262

32

  1. 95% confidence intervals in brackets, results of median regression
  2. * p < 0.1, ** p < 0.05, *** p < 0.01
  3. Results of multivariate quantile regressions including a case-control variable as well as CCI, sex, age, and age2 as fixed effects (HAP and CAP) and MDR-status as effect modifier. For HD-CAP cases univariate quantile regression was used